High dose BI 3812465 Clinical Trials (2026): 1 Studies for Diabetic Macular Edema
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 High dose BI 3812465 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Diabetic Macular Edema) and 49 total planned enrollment. 1 High dose BI 3812465 clinical trial is actively recruiting at 1 U.S. site across 1 state. Most recent activity: NCT07553429 (Jul 2027).
Where to Participate: All High dose BI 3812465 Trial Sites in the U.S. (1 site across 1 state)
Every actively recruiting High dose BI 3812465trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | Global Research Management | Glendale91204 | NCT07553429 | Map |
High dose BI 3812465 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1/P2 | 1 | 1 |
Recruiting High dose BI 3812465 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07553429 | A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated | P1/P2 | Diabetic Macular Edema | 49 | May 2026 |
All High dose BI 3812465 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07553429 | A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated | P1/P2 | recruiting | 49 | Boehringer Ingelheim | May 2026 |
High dose BI 3812465 clinical trials: frequently asked questions
- How many High dose BI 3812465 clinical trials are there?
- 1 High dose BI 3812465 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are High dose BI 3812465 clinical trials recruiting in 2026?
- Yes — 1 High dose BI 3812465 trial is actively recruiting in 2026, with 1 U.S. site across 1 state. See the recruiting trials and the per-state site list further down this page.
- What conditions is High dose BI 3812465 being studied for?
- High dose BI 3812465 is being studied for Diabetic Macular Edema. The trials are grouped by indication on this page.
- Who sponsors High dose BI 3812465 clinical trials?
- The lead sponsor across the most High dose BI 3812465 trials is Boehringer Ingelheim. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming High dose BI 3812465as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: